You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage II grade 2 follicular lymphoma

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Aberdeen, United Kingdom
  • +24 more
Apr 28, 2023

Follicular Lymphoma Trial in Italy (Radiotherapy, Radiotherapy plus Obinotuzumab)

Not yet recruiting
  • Follicular Lymphoma
  • Radiotherapy
  • Radiotherapy plus Obinotuzumab
  • Alessandria, Italy
  • +47 more
Jun 26, 2023

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

Lymphoma Trial in Norway, Sweden, Switzerland (Rituximab, lenalidomide)

Active, not recruiting
  • Lymphoma
  • Bergen, Norway
  • +32 more
Sep 27, 2022

Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial

Completed
Has Results
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
  • +7 more
Nov 4, 2022

Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)

Completed
Has Results
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 30, 2022

AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection Trial (Axicabtagene Ciloleucel,

Not yet recruiting
  • AIDS-Related Diffuse Large B-cell Lymphoma
  • +14 more
  • Axicabtagene Ciloleucel
  • +2 more
  • (no location specified)
Feb 15, 2022

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,

Terminated
Has Results
  • Acute Biphenotypic Leukemia
  • +29 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 4, 2023

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid

Completed
Has Results
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +99 more
  • alemtuzumab
  • +6 more
  • Denver, Colorado
  • +6 more
Jan 15, 2020

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

Withdrawn
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Follicular Lymphoma Trial in Worldwide (tisagenlecleucel)

Active, not recruiting
Has Results
  • Follicular Lymphoma
  • tisagenlecleucel
  • Duarte, California
  • +29 more
Nov 2, 2022

Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Worldwide (Mosunetuzumab SC, Tiragolumab, Atezolizumab)

Recruiting
  • Non-Hodgkin Lymphoma, Follicular Lymphoma
  • Mosunetuzumab SC
  • +3 more
  • Ann Arbor, Michigan
  • +14 more
Aug 12, 2022

Lymphoma Trial in United States (ofatumumab)

Completed
Has Results
  • Lymphoma
  • ofatumumab
  • Lewes, Delaware
  • +47 more
Aug 16, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022